Skip to main navigation

Careers
Investors & Media
Contact

SCIENCE
PIPELINE
DISEASE FOCUS
HAE COMMUNITY
CLINICAL TRIALS
ABOUT US

Events

Investor Menu

IR Nav

Overview
News & Events
News Releases Events Publications
Financials
SEC Filings Quarterly Results
Stock
Stock Performance Analyst Coverage
Corporate Governance
Governance Documents Leadership Board of Directors Committee Composition
Resources
Investor FAQs Contact Us Email Alerts

Past Events

Nov 9 - Nov 13, 2023

ACAAI 2023 Annual Scientific Meeting

Supporting Materials

Deucrictibant immediate-release capsule reduces time to end of progression of hereditary angioedema attacks’ manifestations 207.4 KB

Riedl Audio Recording 7 MB

Understanding the reasons not to treat all HAE attacks and satisfaction for on-demand treatment: physician- and patient-reported data 266.5 KB

Mendivil Audio Recording 5 MB

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

Oct 23 - Oct 26, 2023

APAAACI 2023 International Conference

Supporting Materials

Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule for Treatment of HAE Attacks: Phase 2 Results 1.3 MB

Oct 13 - Oct 14, 2023

CIIC Fall 2023 Conference

Supporting Materials

Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial 4.4 MB

Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule in patients with hereditary angioedema attacks 2.7 MB

Sep 14 - Sep 16, 2023

18th German Allergy Congress

Supporting Materials

Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks (German) à link to Magerl 395.9 KB

Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial (German) à link to Aygoren 484.3 KB

Sep 1 - Sep 3, 2023

HAEi Regional Conference EMEA

Supporting Materials

Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks 1 MB

Efficacy and safety of bradykinin B2 receptor antagonism with oral deucrictibant in prophylaxis of hereditary 319.2 KB

Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial 1 MB

Jul 20 - Jul 23, 2023

U.S. HAEA National Summit

Supporting Materials

Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial 1.8 MB

Treatment with oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule improves hereditary angioedema attack symptoms 1 MB

Jun 23, 2023 9:00 AM EDT

2023 Annual General Meeting of Shareholders

Supporting Materials

Annual Report and Auditor’s Report 2022 4.1 MB

Convening Notice and Agenda 73.7 KB

AGM Announcement 16.4 KB

Voting Proxy 38 KB

Jun 9 - Jun 11, 2023

European Academy of Allergy & Clinical Immunology (EAACI) Congress 2023

Supporting Materials

Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

Treatment with Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 Improves Hereditary Angioedema Attack Symptoms 1.1 MB

Efficacy and Safety of Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe-1 Phase 2 Trial 700.6 KB

May 4 - May 7, 2023

13th C1-inhibitor Deficiency and Angioedema Workshop

Supporting Materials

Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop

The EC85 Derived from the Oral Bradykinin B2 Receptor Antagonist Deucrictibant (PHA121) Against Bradykinin Effects in Healthy Volunteers Predicts the Onset and Duration of Its Clinical Effects in Hereditary Angioedema 1.1 MB

Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate Release Capsule (PHVS416) in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe 1 Phase 2 Trial 870.7 KB

Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks 850.4 KB

Cardiovascular safety of the orally administered bradykinin B2 receptor antagonist, deucrictibant (PHA121, PHA-022121) 1.1 MB

Efficacy of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) by attack location in the RAPIDe-1 phase 2 clinical trial for treatment of hereditary angioedema attacks 1.6 MB

Mar 18, 2023 11:35 AM +07

2023 HAEi Regional Conference APAC

Supporting Materials

Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 920.2 KB

Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

Pagination

First page
Previous page
…
Page 2
Page 3
Current page 4
Page 5
Page 6
Next page
Last page

Presentations

Latest Corporate Presentation

FOLLOW US

©2025 Pharvaris N.V. © All Rights Reserved

Privacy Policy
Terms of Use